Rethinking the Role of Alpha-fetoprotein as a Prognostic Biomarker in the Management of Advanced Hepatocellular
This activity is designed to meet the educational needs ofU.S.-based medical oncologists,particularly those who practice in the community setting, and the multidisciplinary care teamresponsible for treating patients with gastrointestinal tract cancers that include hepatocellularcarcinoma (HCC).
On completion of the program, attendees should be able to:
- Explain how alpha-fetoprotein contributes to HCC tumor immune escape
- Use AFP as a prognostic biomarker for managing advanced HCC, based on the evolution of evidence-based clinical practice guidelines and additional data
- Develop individualized plans for sequencing treatment regimens for patients with advanced HCC based on patient-specific characteristics including AFP levels